Psychopharmacology Bulletin
Patterns of Pharmacotherapy and Treatment Response in Elderly Adults with Bipolar Disorder CME

Disclosures

Release Date: March 25, 2008; Valid for credit through March 25, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

  1. Patterns of Pharmacotherapy and Treatment Response in Elderly Adults with Bipolar Disorder
    John L. Beyer, MD
    Bruce Burchitt, PhD
    Kenneth Gersing, MD
    K. Ranga R. Krishnan, MD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. List challenges in caring for older adults with bipolar disorder
  2. Specify the most commonly used class of medications used to treat bipolar disorder among the elderly
  3. Describe whether monotherapy or combination therapy is more common among older adults with bipolar disorder
  4. Identify the efficacy of treatment for bipolar disorder in elderly adults
Authors and Disclosures

John L. Beyer, MD
Disclosure: John L. Beyer, MD, has disclosed accepting research funding from BMS, Eisai, Elan, GSK, Novartis, Myriad, Pfizer, and Sanofi Synthelabo. Dr. Beyer is also on the Speaker's Bureau of Pfizer and BMS and is a consultant for Eli Lilly.


Bruce Burchitt, PhD
Disclosure: Bruce Burchitt, PhD, has no financial relationships to disclose.


Kenneth Gersing, MD
Disclosure: Kenneth Gersing, MD, has no financial relationships to disclose.


K. Ranga R. Krishnan, MD
Disclosure: K. Ranga R. Krishnan, MD, is a consultant for Amgen, BMS, CeNeRx, Corcept, GSK, J & J, Lundbeck, Merck, Organon, Pfizer, Sepracor and Wyeth.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.